share_log

君聖泰醫藥-B：截至二零二四十二月三十一日止年度的全年業績公告

HIGHTIDE-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2024

HKEX ·  Mar 28 04:00

Summary by Moomoo AI

君聖泰醫藥公佈截至2024年12月31日止年度業績。年內虧損收窄至人民幣3.82億元，較去年同期的人民幣9.39億元大幅減少59.3%。研發成本為人民幣3.64億元，同比增長16.7%，主要用於推進核心產品HTD1801的臨床研究。公司期末現金及現金等價物為人民幣3.11億元。公司核心產品HTD1801研發進展順利。針對2型糖尿病的三期臨床試驗已完成患者入組，預計2025年上半年公佈關鍵數據，並計劃於2025年底前提交新藥申請。針對代謝相關脂肪性肝炎的IIb期研究亦已在美國、中國內地及香港完成患者入組，預計2025年完成。公司持續推進其他在研產品管線，包括HTD4010、HTF1037、HTF1057等7款候選藥物，涵蓋9種適應症。公司已建立全球知識產權組合，擁有134項專利及專利申請，為未來商業化奠定基礎。管理層表示將積極尋找具有強大商業化網絡的合作夥伴，推進HTD1801在多個司法管轄區的商業化。
君聖泰醫藥公佈截至2024年12月31日止年度業績。年內虧損收窄至人民幣3.82億元，較去年同期的人民幣9.39億元大幅減少59.3%。研發成本為人民幣3.64億元，同比增長16.7%，主要用於推進核心產品HTD1801的臨床研究。公司期末現金及現金等價物為人民幣3.11億元。公司核心產品HTD1801研發進展順利。針對2型糖尿病的三期臨床試驗已完成患者入組，預計2025年上半年公佈關鍵數據，並計劃於2025年底前提交新藥申請。針對代謝相關脂肪性肝炎的IIb期研究亦已在美國、中國內地及香港完成患者入組，預計2025年完成。公司持續推進其他在研產品管線，包括HTD4010、HTF1037、HTF1057等7款候選藥物，涵蓋9種適應症。公司已建立全球知識產權組合，擁有134項專利及專利申請，為未來商業化奠定基礎。管理層表示將積極尋找具有強大商業化網絡的合作夥伴，推進HTD1801在多個司法管轄區的商業化。
Junshengtai Pharmaceutical announced its annual performance for the year ending December 31, 2024. The loss for the year narrowed to 0.382 billion RMB, a significant decrease of 59.3% compared to 0.939 billion RMB in the same period last year. R&D costs amounted to 0.364 billion RMB, an increase of 16.7% year-on-year, mainly used for advancing the clinical research of the core product HTD1801. The company's cash and cash equivalents at the end of the period were 0.311 billion RMB.The development progress of the company's core product HTD1801 is smooth. The Phase III clinical trial for type 2 diabetes has completed patient recruitment, with key data expected to be announced in the first half of 2025, and plans to submit a new drug application by the end...Show More
Junshengtai Pharmaceutical announced its annual performance for the year ending December 31, 2024. The loss for the year narrowed to 0.382 billion RMB, a significant decrease of 59.3% compared to 0.939 billion RMB in the same period last year. R&D costs amounted to 0.364 billion RMB, an increase of 16.7% year-on-year, mainly used for advancing the clinical research of the core product HTD1801. The company's cash and cash equivalents at the end of the period were 0.311 billion RMB.The development progress of the company's core product HTD1801 is smooth. The Phase III clinical trial for type 2 diabetes has completed patient recruitment, with key data expected to be announced in the first half of 2025, and plans to submit a new drug application by the end of 2025. The Phase IIb study targeting metabolic associated fatty liver disease has also completed patient recruitment in the USA, China, and Hong Kong, expected to be completed in 2025.The company continues to advance its pipeline of other research products, including HTD4010, HTF1037, HTF1057, and seven other candidate drugs, covering nine indications. The company has established a Global intellectual property portfolio, with 134 patents and patent applications, laying the foundation for future commercialization. Management stated that they will actively seek partners with a strong commercialization network to advance the commercialization of HTD1801 in multiple jurisdictions.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 384

Recommended

Market Insights

Warren Buffett Portfolio Warren Buffett Portfolio

Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.

No. Symbol 5D % Chg
Sample Name
Sample Code
 +7.90%
Sample Name
Sample Code
 +6.00%
Sample Name
Sample Code
 +5.66%
4
Occidental Petroleum
OXY
+5.37%
5
Domino's Pizza
DPZ
+3.70%
Unlock Now

Discussing

Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks Show More
Do you think the trade war will further exacerbate the decline in Chinese stocks?
69%
31%
Yes
No
1021 votes
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Hi, mooers! 👋
The countdown is on! $Alibaba (BABA.US)$ will release its Q4 FY2024 earnings on February 20, just before the market opens. This is your chance to earn rewards and gain insights by predicting the opening price. Let’s get into it! 🎉
Stay Ahead of the Game
Subscribe to @Moo Live for real-time updates, expert analysis, and the live earnings conference stream. Book your spot NOW and be the first to hear the news!
👉 Subscribe Here
Re...

Discussing

FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More
Fed rate cut expectations for 2025 intensify. What’s your market outlook?
44%
56%
Bullish
Bearlish
1593 votes
FOMC Press Conference, March 19, 2025

- No more -

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
OK